P
PSYBF
vs
S&P 500
S&P 500
Over the past 12 months, PSYBF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +15% growth.
Stocks Performance
PSYBF vs S&P 500
Performance Gap
PSYBF vs S&P 500
Performance By Year
PSYBF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Psybio Therapeutics Corp
Glance View
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.